Antimicrobial susceptibility testing of Burkholderia cepacia complex (BCC)

The organism
The B. cepacia complex (BCC) is a group of closely-related species that are ubiquitous in
nature and found particularly in soil and water.1-4 Clinically they are predominantly
associated with chronic pulmonary infection in patients with cystic fibrosis, but may also
cause infections in immunocompromised patients, including those with Chronic
Granulomatous Disease.
Antimicrobial resistance
BCC are resistant to many antimicrobial agents. A lack of binding sites on the
lipopolysaccharide of BCC leads to intrinsic resistance to the cationic antimicrobials,
polymyxins and aminoglycosides.5 BCC can also be resistant to many or all available β-
lactams due to a combination of impermeability and inducible chromosomal β-lactamases. 6,7
Apart from intrinsic low outer membrane permeability,8 at least one efflux pump system has
been described that confers intrinsic resistance to tetracycline, chloramphenicol and
ciprofloxacin.9 The potential presence of these resistance mechanisms means that multiple
drug resistance is common. In one study, 50% of isolates were resistant in vitro to all 10
commonly used agents tested.10
A recent Cochrane Systematic Review concluded “There is a lack of trial evidence to guide
decision making and no conclusions can be drawn from this review about the optimal
antibiotic regimens for cystic fibrosis patients with chronic Burkholderia cepacia complex
infections. Clinicians must continue to assess each patient individually, taking into account in
antibiotic susceptibility data, previous clinical responses and their own experience.”11
Unfortunately, evidence to describe a relationship between the in vitro susceptibility to any
specific antimicrobial agent and clinical outcome is lacking. This is due to a potential
mismatch between the in vivo and in vitro expression of resistance as BCC are known to
exist in biofilms in vivo, and may also invade and survive inside airway epithelial cells and
macrophages.12 Also BCC is frequently treated as a mixed infection, with combinations of
antimicrobials, so that it can be impossible to correlate the outcome with specific activity of a
particular antimicrobial agent against BCC.

Antimicrobial susceptibility testing
It is not currently possible to establish MIC breakpoints for BCC organisms as:
• There is no evidence to describe a relationship between MIC and outcome. • BCC is frequently part of a mixed infection • The MIC distribution of BCC for relevant antimicrobials is wide and encompasses the non-species related pharmacodynamic breakpoint. Therefore the epidemiological cut-off value cannot be used to define the wild-type population as either susceptibile or resistant. Susceptibility testing methodology is problematic: • MIC determination by the ISO broth microdilution (BMD) method with Mueller-Hinton • MIC determination by the gradient strip method is less reproducible than BMD. Antimicrobial susceptibility testing of Burkholderia cepacia complex (BCC), 19 July 2013 Page 1 of 2 • The correlation between the MIC by the ISO BMD method and disk diffusion zone diameters is poor when tested by EUCAST (on MH agar) or BSAC (on Isosensitest agar) methods.
While the ISO BMD method may give reproducible MIC results (gradient MIC and disk
diffusion methods are not reproducible), it is currently not possible to recommend
susceptibility testing of BCC organisms to guide patient therapy.
1. Coenye, T., P. Vandamme, J. R. Govan, and J. J. Lipuma. 2001. Taxonomy and
identification of the Burkholderia cepacia complex. J.Clin.Microbiol. 39:3427-3436.
doi:10.1128/JCM.39.10.3427-3436.2001 [doi].
2. Vanlaere, E., J. J. Lipuma, A. Baldwin, D. Henry, B. E. De, E. Mahenthiralingam, D.
Speert, C. Dowson, and P. Vandamme. 2008. Burkholderia latens sp. nov., Burkholderia
diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and
Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex.
Int.J.Syst.Evol.Microbiol. 58:1580-1590. doi:58/7/1580 [pii];10.1099/ijs.0.65634-0 [doi].
Vanlaere, E., A. Baldwin, D. Gevers, D. Henry, B. E. De, J. J. Lipuma, E.
Mahenthiralingam, D. P. Speert, C. Dowson, and P. Vandamme. 2009. Taxon K, a
complex within the Burkholderia cepacia complex, comprises at least two novel species,
Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. Int.J.Syst.Evol.Microbiol.
59:102-111. doi:59/1/102 [pii];10.1099/ijs.0.001123-0 [doi].
4. Mahenthiralingam, E., A. Baldwin, and C. G. Dowson. 2008. Burkholderia cepacia complex
bacteria: opportunistic pathogens with important natural biology. J.Appl.Microbiol. 104:1539-
1551. doi:JAM3706 [pii];10.1111/j.1365-2672.2007.03706.x [doi].
5. Cox, A. D. and S. G. Wilkinson. 1991. Ionizing groups in lipopolysaccharides of
Pseudomonas cepacia in relation to antibiotic resistance. Mol.Microbiol. 5:641-646.
6. Poirel, L., J. M. Rodriguez-Martinez, P. Plesiat, and P. Nordmann. 2009. Naturally
occurring Class A ss-lactamases from the Burkholderia cepacia complex. Antimicrob.Agents
Chemother. 53:876-882. doi:AAC.00946-08 [pii];10.1128/AAC.00946-08 [doi].
7. Papp-Wallace, K. M., M. A. Taracila, J. A. Gatta, N. Ohuchi, R. A. Bonomo, and M.
Nukaga. 2013. Insights into beta-Lactamases from Burkholderia spp., Two Phylogenetically
Related Yet Distinct Resistance Determinants. J.Biol.Chem. doi:M113.458315
[pii];10.1074/jbc.M113.458315 [doi].
8. Hancock, R. E. 1998. Resistance mechanisms in Pseudomonas aeruginosa and other
nonfermentative gram-negative bacteria. Clin.Infect.Dis. 27 Suppl 1:S93-S99.
9. Burns, J. L., C. D. Wadsworth, J. J. Barry, and C. P. Goodall. 1996. Nucleotide sequence
analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane
lipoprotein involved in multiple antibiotic resistance. Antimicrob.Agents Chemother. 40:307-
10. Aaron, S. D., W. Ferris, D. A. Henry, D. P. Speert, and N. E. Macdonald. 2000. Multiple
combination bactericidal antibiotic testing for patients with cystic fibrosis infected with
Burkholderia cepacia. Am.J.Respir.Crit Care Med. 161:1206-1212.
11. Horsley, A. and A. M. Jones. 2012. Antibiotic treatment for Burkholderia cepacia complex in
people with cystic fibrosis experiencing a pulmonary exacerbation.
Cochrane.Database.Syst.Rev. 10:CD009529. doi:10.1002/14651858.CD009529.pub2 [doi].
12. Sajjan, U. S., J. H. Yang, M. B. Hershenson, and J. J. Lipuma. 2006. Intracellular
trafficking and replication of Burkholderia cenocepacia in human cystic fibrosis airway
epithelial cells. Cell Microbiol. 8:1456-1466. doi:CMI724 [pii];10.1111/j.1462-
5822.2006.00724.x [doi].
Antimicrobial susceptibility testing of Burkholderia cepacia complex (BCC), 19 July 2013 Page 2 of 2


Diario oficial de la república de chile

DIARIO OFICIAL DE LA REPUBLICA DE CHILE Lunes 14 de Mayo de 2012 Constitución Política de la República; en las glosas 05,sindicales y trabajadores y trabajadoras interesa-participado durante 2 o más años como dirigente06, 07 y 08 asociada a la partida 15-01-01-24-01-433,dos en participar en el mundo sindical, con el finde Ley Nº 20.557 de Presupuesto del Sector Públicode logra


UnitedHealthcare SignatureValueTM Offered by UnitedHealthcare of California 40/20% Performance HMO Schedule of Benefits (Benefit Package B, Network 3) Effective January 1, 2012 These services are covered as indicated when authorized through your Primary Care Physician in your Participating Medical Group. (Medically Necessary services served by your Participating Medical Group. Please consult y

Copyright © 2010-2019 Pdf Physician Treatment